Evidence map›Paper›PMID 41717226›Full record

ArticleFrontiers in aging neuroscience2026

Neuromelanin, iron and MRI measurements in midbrain tissues of Parkinson's and Alzheimer's subjects.

Fabio A Zucca, Clifford M Cassidy, Michela Sturini, Lauri Tuominen, Fulvio Adorni, Victoria Cheung, Luigi Casella, David Sulzer, Gianni Pezzoli, Ioannis U Isaias and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fabio A Zucca *Institute of Biomedical Technologies, National Research Council of Italy, Segrate, Italy.
Clifford M Cassidy *Institute of Mental Health Research at the Royal, University of Ottawa, Ottawa, ON, Canada.
Michela SturiniDepartment of Chemistry, University of Pavia, Pavia, Italy.
Lauri TuominenInstitute of Mental Health Research at the Royal, University of Ottawa, Ottawa, ON, Canada.
Fulvio AdorniInstitute of Biomedical Technologies, National Research Council of Italy, Segrate, Italy.
Victoria CheungInstitute of Mental Health Research at the Royal, University of Ottawa, Ottawa, ON, Canada.
Luigi CasellaDepartment of Chemistry, University of Pavia, Pavia, Italy.
David SulzerDepartments of Psychiatry, Neurology, and Pharmacology, Columbia University Medical Center, New York, NY, United States.
Gianni PezzoliParkinson Institute of Milan, ASST G. Pini-CTO, Milan, Italy.
Ioannis U IsaiasParkinson Institute of Milan, ASST G. Pini-CTO, Milan, Italy.
Guillermo HorgaDepartment of Psychiatry, Columbia University, New York, NY, United States.
Luigi ZeccaInstitute of Biomedical Technologies, National Research Council of Italy, Segrate, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In Parkinson's disease, decreased neuromelanin and increased Fe concentrations derive from the loss of neuromelanin-containing neurons in the substantia nigra, which is spared in Alzheimer's disease. We aimed to measure neuromelanin and Fe concentrations in post mortem midbrain subregions of patients with Parkinson's and Alzheimer's disease, and to investigate their effect on MRI signals. Methods: We imaged neuromelanin in brain slices of Parkinson's ( Results: Both neuromelanin and Fe concentrations provided unique contributions to neuromelanin-MRI. Compared to Alzheimer's disease, subjects with Parkinson's disease exhibited increased neuromelanin-MRI values in the superior colliculus and periaqueductal gray matter, and higher Fe concentration in the substantia nigra. Conclusion: Results support the use of neuromelanin-MRI to study neuromelanin and Fe in substantia nigra and neighboring regions for investigating patients with Parkinson's disease and other movement disorders.

Indexed as

Alzheimer’s diseaseimaging mapironmagnetic resonance imagingneuromelaninParkinson’s disease

Identifiers

PMID41717226
PMCPMC12913387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.